Synthetic method and application of PBBT and PBBT-Fe nanoparticles

By synthesizing PBBT nanoparticles, the problems of uneven distribution and stability of boron drugs in vivo have been solved, enabling efficient tumor-targeted delivery and visual monitoring of boron drugs, thus improving the therapeutic efficacy and safety of BNCT.

CN118903410APending Publication Date: 2024-11-08SUZHOU UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410843678.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-27
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The uneven distribution and instability of existing boron drugs in vivo lead to poor efficacy of BNCT treatment, and the lack of effective visualization and tracking methods affects the accuracy and safety of treatment.

Method used

The synthesis method of PBBT nanoparticles is adopted. Through the self-aggregation process of polyethylene glycol, bovine serum albumin and boric acid, nanoparticles are formed by combining tannic acid. Optionally, Fe3+ is added to form PBBT-Fe nanoparticles, realizing boron loading and magnetic resonance imaging function.

Benefits of technology

PBBT nanoparticles exhibit excellent monodispersity and biocompatibility, enabling effective delivery of boron drugs to tumor sites. Magnetic resonance imaging can be used to monitor drug distribution, achieving high-concentration boron accumulation and safe delivery at tumor sites.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903410A_ABST
    Figure CN118903410A_ABST
Patent Text Reader

Abstract

The synthetic method comprises the following steps: (1) sequentially and respectively adding a polyethylene glycol solution, bovine serum, a protein solution and a boric acid solution into water, uniformly mixing, and adding a tannic acid solution while performing ultrasonic treatment to initiate a self-aggregation process, so as to obtain a crude product; and (2) centrifuging the crude product to remove larger nanoparticles, taking supernatant, and performing ultrafiltration purification to remove unreacted raw materials to obtain a final product, furthermore, the invention further discloses a synthetic method of the PBBT-Fe nano-particles, before a tannic acid solution is added to initiate self-aggregation, a ferric chloride solution is also added into the tannic acid solution, and the synthetic method realizes successful loading of boron and the nano-particles with boron loading and magnetic resonance imaging functions. The dual purposes of delivering boron to a tumor site and monitoring in-vivo drug distribution through magnetic resonance imaging are achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a synthesis method of PBBT and PBBT-Fe nanoparticles and application thereof. Background Art

[0002] Boron neutron capture therapy (BNCT), as a new targeted precision radiotherapy method, has developed rapidly in recent years and has shown good therapeutic effects on some refractory tumors, such as glioma, head and neck tumors, and melanoma. In order to successfully carry out BNCT, two factors need to be met: 10 B and neutron irradiation. 10 When drug B accumulates in the tumor site, neutron irradiation is performed. 10 B absorbs neutrons and fuses to generate excited states 11 B, 11 B splits into alpha particles in an instant 7 Li is a high linear energy delivery beam with a range of 4-10 μm, which is limited to the size of a single cell. Compared with traditional radiotherapy, BNCT significantly reduces damage to normal tissues and increases tumor targeting, which can be used to selectively irradiate tumors while minimizing radiation damage to non-tumor tissues.

[0003] BNCT is a national key development project. The development of accelerators and neutron sources has enabled it to penetrate human tissues at different depths. Therefore, the main problem of BNCT at present is to find boron-containing drugs that can meet the treatment needs. Rational boron drugs should meet the following standards: 1. Low biological toxicity: safe boron drugs can be administered multiple times or for a long time to increase the boron concentration in the tumor site; 2. 10 The cumulative concentration of B reaches 20-50 μg / g and can be maintained at a high concentration during neutron irradiation; 3. Tumor specificity: tumor / normal tissue (T / N ratio) and tumor / blood 10 The B concentration ratio (T / B ratio) is greater than 3 to ensure that tumor cells are killed while avoiding damage to normal tissues as much as possible. In addition, boron drugs should also have excellent stability to ensure their effectiveness under complex physiological conditions. In order to meet the standards of boron drugs, a variety of boron drugs have been developed, from the initial boric acid and borax to borophenylalanine (BPA) and sodium borocarbonate (BSH) currently used in clinical or clinical trials, to the various boron-containing small molecules, macromolecules and nano drugs that are now booming. Their performance has been improved in many aspects, but there are still problems that need to be solved.

[0004] In addition, the distribution of boron drugs in the body plays a decisive role in the successful implementation of BNCT. Therefore, the use of visualization methods to track 10The biodistribution of B is of great significance for accurately guiding the implementation of BNCT. Summary of the invention

[0005] The purpose of the present invention is to provide a method for synthesizing PBBT nanoparticles, synthesizing boron-loaded nanomedicines, and achieving the purpose of delivering 10B to tumor sites.

[0006] The technical solution of the present invention is: a method for synthesizing PBBT nanoparticles, comprising the following steps:

[0007] (1) Add polyethylene glycol solution, bovine serum albumin solution, and boric acid solution to water in order, mix well, and then add tannic acid solution while ultrasonicating to initiate a self-aggregation process to obtain a crude product.

[0008] (2) The crude product is centrifuged to remove larger nanoparticles, and the supernatant is ultrafiltered to remove unreacted raw materials to obtain the final product, which is denoted as PEG-BSA-10BA-TA, abbreviated as PBBT, wherein the boron element is 10B.

[0009] Preferably, the mass ratio of polyethylene glycol, bovine serum albumin and boric acid is 1:2.5:12.5.

[0010] Preferably, the molecular weight of polyethylene glycol in the polyethylene glycol solution is 1000-10000, and the concentration of polyethylene glycol is 10-50 mg / mL.

[0011] Preferably, the concentration of bovine serum albumin in the bovine serum albumin solution is 10-20 mg / mL.

[0012] Preferably, the concentration of boric acid in the boric acid solution is 50-100 mg / mL.

[0013] Preferably, the tannic acid concentration in the tannic acid solution is 5 mg / mL. If the concentration is too high, nanoparticles cannot be formed and will be directly precipitated. If the concentration is too low, the boron loading amount will be reduced.

[0014] Preferably, the boric acid solution is prepared by dissolving boric acid in a Tris buffer solution with a pH value of ≥ 8.8 and completely dissolving the boric acid by ultrasonication.

[0015] The ultrafiltration membrane used for ultrafiltration had MWCO=100 kDa.

[0016] The present invention also provides a method for synthesizing PBBT-Fe nanoparticles, including the above-mentioned method for synthesizing PBBT nanoparticles, wherein the specific step (1) is: adding polyethylene glycol solution, bovine serum albumin solution, and boric acid solution to water in order, adding Fe3+-containing solution thereto, mixing them evenly, and then adding tannic acid solution while ultrasonicating to initiate a self-aggregation process to obtain a crude product.

[0017] The PBBT-Fe nanoparticles synthesized by this method are nanodrugs with boron loading and magnetic resonance imaging functions, which can achieve the purpose of delivering 10B to tumor sites and visualizing the distribution of boron drugs.

[0018] Preferably, the Fe3+-containing solution is an aqueous solution of ferric chloride, the mass ratio of ferric chloride to polyethylene glycol is 4:5, and the concentration of ferric chloride in the ferric chloride solution is 5 mg / mL. Too high a concentration will produce precipitation, and a low concentration will lead to a decrease in the content of Fe and B, further resulting in a decrease in the relaxation rate and boron loading.

[0019] The present invention also provides the use of the above-mentioned PBBT nanoparticles or PBBT-Fe nanoparticles in PET imaging agents for treating tumors.

[0020] The advantages of the present invention are:

[0021] 1. The synthesis and purification conditions of PBBT nanoparticles are simple, which is conducive to the subsequent amplification synthesis; its average size is 4.63±0.90nm, the hydrated particle size is 98.46nm, and it has excellent monodispersity. At the same time, ultraviolet absorption spectroscopy, Fourier transform infrared spectroscopy and X-ray photoelectron spectroscopy further demonstrate that PBBT nanoparticles have achieved successful boron loading.

[0022] 2. The average size of PBBT-Fe nanoparticles formed after chelation of PBBT nanoparticles with Fe3+ is 3.12±0.46nm, and the hydrated particle size is 98.99nm. Combined with other characterization methods, it further illustrates the successful loading of Fe3+. At the same time, the relaxation rate test shows that its longitudinal relaxation rate is 4.18mM-1s-1, which can be used as a T1 contrast agent for MRI. This shows that the distribution of PBBT nanoparticles in the body can be tracked by PBBT-Fe nanoparticles through magnetic resonance imaging, which can achieve the dual purpose of delivering boron to the tumor site and monitoring the distribution of drugs in the body through magnetic resonance imaging.

[0023] 3. At the cellular level, PBBT nanoparticles have good biocompatibility and can be effectively taken up by tumor cells.

[0024] 4. At the animal level, magnetic resonance imaging was performed after intravenous injection of PBBT-Fe nanoparticles (injection dose of 7 mg Fe / mL). The T1-weighted images obtained using the FSE sequence showed that after the injection of nanoparticles, the signal at the tumor site gradually increased, reached a peak at 24 hours, and maintained a long-term enhancement, indicating that PBBT nanoparticles can be well absorbed.

[0025] 5. PBBT nanoparticles have excellent biosafety. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1This is a schematic diagram of the synthesis of PBBT nanoparticles in Example 1.

[0027] Figure 2 (a) TEM image and particle size distribution histogram (scale bar is 20 nm) of PBBT nanoparticles in Example 1, (b) hydrated particle size distribution. (c) UV absorption spectra of PBBT nanoparticles, TA and BSA solutions. (d) Fourier infrared absorption spectra of PBBT nanoparticles, PEG, BSA, BA and TA. (e) X-ray photoelectron spectrum of PBBT nanoparticles.

[0028] Figure 3 Schematic diagram of the synthesis of PBBT-Fe nanoparticles in Example 2.

[0029] Figure 4 (a) TEM image and particle size distribution histogram (scale bar is 20 nm) of PBBT-Fe nanoparticles of Example 2, (b) hydrated particle size distribution, (c) X-ray photoelectron spectrum. (d) Potential change diagram of PBBT nanoparticles and PBBT-Fe nanoparticles, (e) UV absorption spectrum change, (f) Fourier infrared spectrum change.

[0030] Figure 5 (a) The relaxation time of PBBT-Fe nanoparticles at different concentrations in Example 2, the longitudinal and transverse relaxation rates obtained by linear fitting, and (b) the T1-weighted and T2-weighted images at different concentrations.

[0031] Figure 6 This is Example 3: The cytotoxicity of PBBT nanoparticles to (a) 3T3 cells and (b) B16F10 cells.

[0032] Figure 7 This is the uptake of B by B16F10 cells after incubation with PBBT nanoparticles for different time periods in Example 4.

[0033] Figure 8 (a) T1-weighted MR images obtained using FSE sequence at different time points after tail vein injection of PBBT-Fe nanoparticles in Example 5 and (b) signal circle values ​​of the tumor site at the corresponding time points.

[0034] Fig. 9 (a) Blood routine test of mice and (b) HE sections of major organs 28 days after tail vein injection of PBBT nanoparticles in Example 6 (scale bar: 200 μm). Specific embodiments

[0035] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it. However, the embodiments are not intended to limit the present invention.

[0036] Embodiment 1:

[0037] This example involves the synthesis and characterization of PBBT nanoparticles, and the specific process is as follows:

[0038] Synthesis method of PBBT nanoparticles:

[0039] (1) Polyethylene glycol 1000 (200 mg), bovine serum albumin (100 mg) and tannic acid (50 mg) were dissolved in 10 mL of ultrapure water respectively and completely dissolved by sonication; boric acid (500 mg) was dissolved in 10 mL of Tris buffer (pH = 8.8) and completely dissolved by sonication.

[0040] (2) Add 20 μL, 100 μL, and 100 μL of polyethylene glycol, bovine serum albumin, and boric acid to 2 mL of water in that order, mix well, then add 200 μL of tannic acid solution while ultrasonicating to initiate the self-aggregation process, and continue ultrasonicating for 20 min to obtain a crude product.

[0041] (3) The crude product was centrifuged to remove larger nanoparticles, and the supernatant was purified by ultrafiltration (MWCO = 100 kDa). This was repeated three times to remove unreacted raw materials to obtain the final product, which was recorded as PEG-BSA-BA-TA, abbreviated as PBBT.

[0042] Characterization of PBBT nanoparticles: In order to determine the morphology and size of PBBT nanoparticles, the solution was diluted to an appropriate concentration and then dropped onto a copper mesh. After natural air drying, a Talos F200S G2 transmission electron microscope was used to take TEM images at an accelerating voltage of 200kV, and the particle size distribution of the nanoparticles in the electron microscope image was statistically analyzed using Image J software. At the same time, the hydrodynamic size and Zeta potential were measured at 25°C using a Malvern ZS90Zeta meter and a solid-state He-Ne laser (λ=633nm). In order to characterize the composition of PBBT nanoparticles, the solution was diluted to an appropriate concentration and the absorption spectrum was tested using an ultraviolet spectrophotometer; the Fourier infrared spectrum and X-ray photoelectron spectrum of the PBBT nanoparticle solution were tested after freeze-drying to further illustrate the composition of the PBBT nanoparticles and the forces involved in the formation of the nanoparticles. The results are shown in Figure 2 As shown, the average size of BBT nanoparticles is 4.63 ± 0.90 nm, the hydrated particle size is 98.46 nm, and it has excellent monodispersity. Figure 2c It can be seen that the absorption spectrum of PBBT nanoparticle solution has characteristic absorption peaks of tannic acid and bovine serum albumin, indicating that TA and BSA participate in the formation of nanoparticles. Figure 2 d shows that the characteristic peaks of -CH2 of PEG, -CO-NH- and -BOC of BSA can be seen in the Fourier infrared spectrum, indicating that PBBT nanoparticles contain PEG and BSA, and boron loading is achieved through borate ester bonds. Figure 2 It can be seen that the characteristic binding energy peaks of S2p, B 1s, and N 1s can be seen in the X-ray photoelectron spectrum, indicating that the PBBT nanoparticles contain BSA and successfully achieve the loading of BA. The ultraviolet absorption spectrum, Fourier transform infrared spectrum and X-ray photoelectron spectrum further illustrate that the PBBT nanoparticles have achieved the successful loading of boron.

[0043] Embodiment 2:

[0044] This example involves the synthesis and characterization of PBBT-Fe nanoparticles, and the specific process is as follows:

[0045] Synthesis method of PBBT-Fe nanoparticles:

[0046] (1) Dissolve polyethylene glycol 1000 (200 mg), bovine serum albumin (100 mg), anhydrous ferric chloride (50 mg) and tannic acid (50 mg) in 10 mL of ultrapure water, respectively, and dissolve them completely by sonication; dissolve boric acid (500 mg) in 10 mL of Tris buffer (pH = 8.8), and dissolve them completely by sonication.

[0047] (2) Add 20 μL, 100 μL, 100 μL, and 64 μL of polyethylene glycol, bovine serum albumin, boric acid, and ferric chloride to 2 mL of water in that order, mix well, add 200 μL of tannic acid solution while ultrasonicating, and continue ultrasonicating for 20 min to obtain a crude product.

[0048] (3) The crude product was centrifuged to remove larger nanoparticles, and the supernatant was purified by ultrafiltration (MWCO = 100 kDa). This was repeated three times to remove unreacted raw materials to obtain the final product, which was recorded as PEG-BSA-BA-TA-Fe, abbreviated as PBBT-Fe.

[0049] Characterization of PBBT-Fe nanoparticles: The characterization method of PBBT-Fe nanoparticles is the same as that of PBBT nanoparticles. Figure 4 As shown, the average size of PBBT-Fe nanoparticles is 3.12±0.46nm, and the hydrated particle size is 98.99nm. Figure 4 c shows that the characteristic binding energy peaks of S2p, B 1s, N 1s, and Fe are visible in the X-ray photoelectron spectroscopy data, proving the successful loading of Fe3+. Figure 4 d shows that the potential of PBBT-Fe is slightly positive relative to that of PBBT. This is because Fe3+ is positively charged, so the potential of PBBT-Fe is closer to neutral. Figure 4 e shows that the UV absorption spectrum of PBBT-Fe has a broad absorption in addition to the absorption peaks of TA and BSA relative to PBBT, proving the successful loading of Fe3+.

[0050] In addition, in order to characterize the relaxation properties of PBBT-Fe nanoparticles, we tested the relaxation time T1 and T2 of Magnevist and PBBT-Fe nanoparticles and scanned T1 and T2 weighted images on a preclinical 3T small animal magnetic resonance imaging instrument. The longitudinal relaxation time T1 was measured using an inversion recovery fast small angle excitation sequence, and the parameters used were: repetition time TR = 12ms, echo time TE = 768ms, inversion angle FA = 8°, inversion time TI = 74-6170ms, scanning field of view FOV = 40×40mm, and layer thickness Thickness = 2.0mm. The transverse relaxation time T2 was measured using a multi-echo spin echo sequence, and the parameters used were: TR = 1400ms, TE = 15-450ms, FOV = 40×40mm, and Thickness = 2.0mm. Both T1-weighted and T2-weighted images were obtained using a fast spin echo sequence. The parameters used for T1-weighted image scanning are: TR = 750ms, TE = 11ms, FA = 90°, ETL = 1, FOV = 40×40mm, Thickness = 2.0mm, and number of scans NEX = 1. The scanning parameters of T2-weighted images are the same as those of T1-weighted images except TR = 5000ms and TE = 68ms. Figure 5 As shown, the relaxation rate test showed that its longitudinal relaxation rate was 4.18mM-1s-1, which can be used as T1 contrast agent image of MRI.

[0051] Embodiment three:

[0052] This example relates to the cytotoxicity of PBBT nanoparticles to B16F10 melanoma cells and 3T3 fibroblasts.

[0053] The specific implementation plan is as follows:

[0054] (1) Prepare a cell suspension of B16F10 cells in the logarithmic growth phase, add 200 μL of the cell suspension to a 96-well plate at a density of 1×104 / well, and incubate in an incubator for 24 h to ensure that the cells are completely attached to the plate and in good condition.

[0055] (2) After removing the old culture medium and rinsing with PBS, 200 μL of PBBT nanoparticle solution of corresponding concentration (n=3) was added to each well and incubated in an incubator for 24 h.

[0056] (3) After the incubation, the culture medium was removed and the cells were rinsed with PBS. Then, 200 μL of complete culture medium containing 10% CCK8 was added to each well. The cells were placed in an incubator for a corresponding period of time for color development and then the absorbance at 450 nm was detected and recorded using an enzyme reader.

[0057] (4) Finally, the relative survival rate of the cells was calculated according to the formula: relative survival rate of the cells (%) = (absorbance of the experimental group - absorbance of the blank sample) / (absorbance of the control group - absorbance of the blank sample) × 100%. The absorbance of the experimental group is the average absorbance after incubation of the cells with different concentrations of the material, the absorbance of the blank sample is the average absorbance of the complete culture medium, and the absorbance of the control group is the average absorbance of the cells without any treatment.

[0058] The results are as follows Figure 6 As shown, after co-incubation with PBBT nanoparticles, normal 3T3 cells have high activity, while most melanoma B16 cells die. This shows that PBBT nanoparticles have high biocompatibility for normal cells and have certain anti-cancer effects.

[0059] Embodiment 4:

[0060] This example relates to the cellular uptake of PBBT nanoparticles by B16F10 cells at different times.

[0061] The specific implementation plan is as follows:

[0062] (1) B16F10 melanoma cells were seeded in a 6-well plate at a density of 8×105 W / mL and incubated in an incubator for 24 h to allow them to fully adhere to the plate.

[0063] (2) After removing the old culture medium and rinsing with PBS, 15 μg B / mL PBBT nanoparticle solution was added. The experimental time points were set at 30 min, 2 h, 4 h, and 10 h, with three replicate wells at each time point.

[0064] (3) After incubation in a cell culture incubator for a corresponding time point, the old culture medium was removed and the cells were rinsed twice with PBS buffer to remove free nanoparticles and cell debris. After trypsin digestion and termination of digestion with complete culture medium, the cell pellets were obtained by centrifugation.

[0065] (4) Resuspend the cells with 1 mL of PBS and centrifuge. Repeat the washing process twice. Resuspend the resulting cell pellet with PBS and count the cells.

[0066] (5) After centrifugation again to obtain the cell pellet, 0.5 mL of concentrated nitric acid was added for digestion overnight, and then the volume was adjusted to 5 mL with ultrapure water. The B concentration in the sample was tested by inductively coupled plasma emission spectrometry.

[0067] The results are as follows Figure 7 As shown in the figure, the concentration of boron in tumor cells B16F10 cells tends to decrease over time. It is speculated that this is because the boronate bond is pH sensitive. After entering the cell, the acidic environment in the lysosome causes the boronate bond to break and release small molecular boric acid, which is easier to be excreted by the cell, so the boron in the tumor cells gradually decreases.

[0068] Embodiment five:

[0069] This example involves T1-weighted magnetic resonance imaging of subcutaneous B16F10 tumors using PBBT-Fe nanoparticles.

[0070] BALB / C mice (18-20 g, 4-5 weeks old) bearing B16F10 tumors with a tumor volume of 80-150 mm3 were taken and anesthetized with 3.5% isoflurane to ensure that they were in a stable state. The mice were fixed in a prone position on a mouse animal bed dedicated to a 3T small animal magnetic resonance imaging system, and isoflurane was continuously supplied through a nose cone device on the animal bed to maintain the anesthesia of the mice. During the scan, the position of the animal bed was adjusted to ensure that the tumor site was consistent with the coil scanning center. Subsequently, a magnetic resonance scan was performed, and the isoflurane concentration was maintained at 1% during the magnetic resonance scan. First, a positioning image was obtained, and after determining the scanning range, a coronal image of the mouse was obtained based on the FLASH sequence, and then a transverse T1-weighted scan of the mouse was performed based on the FSE sequence to obtain a magnetic resonance image (PRE) without injection of PBBT-Fe nanoparticles. After the PRE scan, PBBT-Fe was intravenously injected into the mice, and T1-weighted transverse images were obtained by magnetic resonance scanning at different time points after injection (4h, 24h, 48h, 72h, and 96h). After the scan, the magnetic resonance imaging signal of the region of interest (ROI) in the obtained image was circled, recorded, and analyzed using the imaging system software.

[0071] The scanning parameters of transverse T1-weighted imaging were: TR=750ms, TE=11ms, FOV=40mm×40mm, Thickness=1mm.

[0072] The scanning parameters of coronal FLASH imaging were: TR=20ms, TE=4ms, Thickness=1mm, FOV=50×50mm, and matrix was 194×152.

[0073] The results are as follows Figure 8 As shown, the magnetic resonance signal at the tumor site gradually increased with time, reached a peak at 24 hours, and continued to maintain a high signal, indicating that PBBT-Fe nanoparticles continued to exist at the tumor site.

[0074] Embodiment six:

[0075] This example relates to the long-term biosafety assessment of PBBT nanoparticles.

[0076] Several normal BALB / C mice were taken and divided into 2 groups (normal saline group and PBBT group), with 3 mice in each group. Normal saline was injected into the tail vein of each mouse in the control group, and PBBT nanoparticle solution was injected into the tail vein of each mouse in the experimental group. They were raised normally for 28 days after injection. After a 28-day experimental period, blood samples of the mice were collected through the orbital vein and blood routine indicators were tested. The mice were then euthanized and dissected to obtain the main organs such as the heart, liver, spleen, lungs and kidneys. To ensure the integrity of the tissue morphology, these tissues were fixed with 4% paraformaldehyde fixative, and then each tissue was sectioned and stained with hematoxylin-eosin. Finally, an inverted fluorescence microscope was used to observe the stained tissue sections and take images.

[0077] The results are as follows Fig. 9 As shown, there was no significant difference in the blood routine and major organs of mice injected with PBBT nanoparticles compared with the control group, proving that PBBT nanoparticles have excellent long-term biosafety.

[0078] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.

Claims

1. A method for synthesizing PBBT nanoparticles, characterized in that: The steps include: (1) Add polyethylene glycol solution, bovine serum albumin solution, and boric acid solution to water in order, mix well, and then add tannic acid solution while ultrasonicating to initiate a self-aggregation process to obtain a crude product. (2) The crude product was centrifuged to remove larger nanoparticles, and the supernatant was ultrafiltered to remove unreacted raw materials to obtain the final product, which was recorded as PEG-BSA-10BA-TA, abbreviated as PBBT, in which the boron element is 10 B.

2. A method for synthesizing PBBT nanoparticles according to claim 1, characterized in that: The mass ratio of polyethylene glycol, bovine serum albumin and boric acid is 1:2.5:12.

5.

3. A method for synthesizing PBBT nanoparticles according to claim 2, characterized in that: The molecular weight of polyethylene glycol in the polyethylene glycol solution is 1000-10000, and the concentration of polyethylene glycol is 10-50 mg / mL.

4. A method for synthesizing PBBT nanoparticles according to claim 2, characterized in that: The concentration of bovine serum albumin in the bovine serum albumin solution is 10-20 mg / mL.

5. A method for synthesizing PBBT nanoparticles according to claim 2, characterized in that: The concentration of boric acid in the boric acid solution is 50-100 mg / mL.

6. A method for synthesizing PBBT nanoparticles according to claim 2, characterized in that: The tannic acid concentration in the tannic acid solution is 5 mg / mL.

7. A method for synthesizing PBBT nanoparticles according to claim 2, characterized in that: The boric acid solution is prepared by dissolving boric acid in a Tris buffer solution with a pH value of ≥ 8.8 and completely dissolving the boric acid by ultrasonication.

8. A method for synthesizing PBBT-Fe nanoparticles, comprising the method for synthesizing PBBT nanoparticles according to claim 1, characterized in that: The specific step (1) is to add polyethylene glycol solution, bovine serum albumin solution and boric acid solution into water in order, then add Fe3+-containing solution, mix well, and then add tannic acid solution while ultrasonicating to induce self-aggregation process to obtain a crude product.

9. The method for synthesizing PBBT-Fe nanoparticles according to claim 9, characterized in that: The Fe3+-containing solution is a ferric chloride aqueous solution, the mass ratio of ferric chloride to polyethylene glycol is 4:5, and the concentration of ferric chloride in the ferric chloride solution is 5 mg / mL.

10. Use of the PBBT nanoparticles according to claim 1 or the PBBT-Fe nanoparticles according to claim 8 in PET imaging agents for treating tumors.

Citation Information

Cited By

  • Boron manganese tannate nanoparticles as well as synthesis method and application thereof

    CN119523944A